Dec. 6 , 2007 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its corporate partner, Pfizer (NYSE: PFE), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for the treatment of allergic asthma. R343 is the third product candidate in Rigel's clinical portfolio... Rigel's Press Release -
